Cervical cancer, human papillomavirus and vaccines.
HPV-16 has been strongly implicated in the aetiology of cervical cancer and pre-malignant cervical intraepithelial neoplasia. Despite current technical difficulties it may soon be possible to treat these tumours with anti-HPV-16 vaccines. A prophylactic vaccine could, in theory, be developed to induce neutralizing antibodies to HPV-16 virions in genital secretions, and a therapeutic vaccine to elicit cytotoxic T-cell responses against established lesions.
Khan
S A
SA
United Medical School, Guy's Hospital (UMDS), London, UK.
D000818:Animals; D005260:Female; D006801:Humans; D027383:Papillomaviridae / Q000276:immunology; D030361:Papillomavirus Infections / Q000276:immunology / Q000628:therapy*; D053918:Papillomavirus Vaccines; D014412:Tumor Virus Infections / Q000276:immunology / Q000628:therapy*; D002583:Uterine Cervical Neoplasms / Q000382:microbiology / Q000517:prevention & control*; D014765:Viral Vaccines; D002578:Uterine Cervical Dysplasia / Q000517:prevention & control*
D053918:Papillomavirus Vaccines; D014765:Viral Vaccines